MOUNJARO 12 5MG KWIKPEN
Item requires a valid prescription
Manufactured By LILLY PRODUCTS
Composition TIRZEPATIDE 12 5MG
RS 25781.20
Package SIZE
( 2.4ML )
100% Authentic
Products
Free
Shipping*
Products
Return Policy
Description:
Mounjaro 12.5mg KwikPen
Mounjaro 12.5mg KwikPen (Tirzepatide 12.5mg) is an injectable prescription medicine manufactured by Eli Lilly and Company, representing the most innovative class of antidiabetic agents — a dual Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptor agonist. Each KwikPen delivers 4 pre-set subcutaneous doses of 12.5mg Tirzepatide, administered once weekly. This is the high-maintenance dose, appropriate for patients who have completed the stepwise dose escalation from 2.5mg through 5mg, 7.5mg, and 10mg. Available from Shabbir Medical Hall with genuine cold-chain delivery across India.
BENEFITS: Mounjaro 12.5mg KwikPen delivers dual hormonal action unlike any other diabetes medication. By simultaneously activating GIP and GLP-1 receptors, Tirzepatide achieves superior HbA1c reduction and clinically meaningful body weight loss — two goals that are critical in the management of Type 2 Diabetes Mellitus. Clinical trials (SURPASS programme) demonstrated HbA1c reductions of up to 2.58% and average body weight reductions of up to 11.2kg at 40 weeks compared to placebo, significantly outperforming leading GLP-1 agonists. Mounjaro is also approved for chronic weight management (Zepbound brand) in adults with obesity or overweight with weight-related comorbidities.
USAGE OVERVIEW: Mounjaro 12.5mg is injected subcutaneously once weekly into the abdomen, thigh, or upper arm — at any time of day, with or without food. It must be used only under the supervision of a diabetologist or endocrinologist, as part of a comprehensive diabetes management and lifestyle modification programme.
SAFETY OVERVIEW: The most common side effects include nausea, vomiting, diarrhoea, decreased appetite, and abdominal discomfort, typically seen during dose escalation and resolving with time. Serious risks include acute pancreatitis, acute gallbladder disease, and a theoretical risk of thyroid C-cell tumours (observed in animal studies). Mounjaro is contraindicated in individuals with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Uses / Indications:
PRIMARY USES:
• Type 2 Diabetes Mellitus (T2DM): As an adjunct to diet and exercise to improve glycaemic control in adults with T2DM — starting from 2.5mg with dose escalation to 12.5mg based on tolerability and glycaemic response
• Chronic Weight Management (Obesity / Overweight): Approved (as Zepbound) for adults with BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidaemia, T2DM, obstructive sleep apnoea)
• Cardiovascular Risk Reduction: Clinical evidence from SURPASS-CVOT trial demonstrates cardiovascular outcome benefits in high-risk T2DM patients
ADDITIONAL USES:
• Combination therapy: Used with Metformin, SGLT2 inhibitors (Empagliflozin, Dapagliflozin), or basal insulin in inadequately controlled T2DM
• Body weight reduction: The most potent injectable weight-loss effect available among approved antidiabetic agents
• Blood pressure and lipid improvement: Modest but consistent reductions in systolic BP and triglycerides as secondary benefits
• Type 2 Diabetes Mellitus (T2DM): As an adjunct to diet and exercise to improve glycaemic control in adults with T2DM — starting from 2.5mg with dose escalation to 12.5mg based on tolerability and glycaemic response
• Chronic Weight Management (Obesity / Overweight): Approved (as Zepbound) for adults with BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidaemia, T2DM, obstructive sleep apnoea)
• Cardiovascular Risk Reduction: Clinical evidence from SURPASS-CVOT trial demonstrates cardiovascular outcome benefits in high-risk T2DM patients
ADDITIONAL USES:
• Combination therapy: Used with Metformin, SGLT2 inhibitors (Empagliflozin, Dapagliflozin), or basal insulin in inadequately controlled T2DM
• Body weight reduction: The most potent injectable weight-loss effect available among approved antidiabetic agents
• Blood pressure and lipid improvement: Modest but consistent reductions in systolic BP and triglycerides as secondary benefits
Interactions / Warnings:
PRE-TREATMENT SCREENING (MANDATORY): Personal and family history: Screen for MTC or MEN 2 — absolute contraindication if positive history. Pancreatitis history: Relative contraindication — discuss benefit/risk with specialist. HbA1c, fasting blood glucose, post-prandial glucose — baseline before initiation. Renal function, liver function — baseline documentation. Gallbladder ultrasound: Consider if history of gallstones. Body weight, BMI, blood pressure — document baseline.
CONTRAINDICATIONS: Personal or family history of MTC or MEN 2. Active or history of pancreatitis (relative). Pregnancy or breastfeeding. Type 1 Diabetes Mellitus. Severe gastrointestinal disease (gastroparesis).
SICK-DAY / PROCEDURE RULES: Tirzepatide does NOT require dose withholding before surgery (unlike SGLT2 inhibitors). However, if severely unwell with inability to eat/drink, discuss with physician about temporary dose hold. Monitor for dehydration if persistent vomiting/diarrhoea — ensure adequate fluid intake.
CARDIOVASCULAR MONITORING: Modest heart rate increase (~2–4 bpm) — not clinically significant in most patients. Monitor in patients with pre-existing arrhythmias or tachycardia.
Pregnancy interaction:
• Mounjaro 12.5mg (Tirzepatide) is CONTRAINDICATED in pregnancy — limited human data; animal studies showed adverse foetal effects
• Women of childbearing potential should use effective contraception while taking Tirzepatide
• Discontinue Mounjaro at least 1 month before a planned pregnancy (half-life approximately 5 days; wash-out recommended)
• If pregnancy is detected during treatment, discontinue immediately and switch to Insulin (preferred antidiabetic in pregnancy)
BREASTFEEDING:
• Tirzepatide is NOT recommended during breastfeeding — unknown whether excreted in human breast milk; risk to nursing infant cannot be excluded
• Discontinue breastfeeding or discontinue Mounjaro, weighing benefit of breastfeeding to infant
CONTRACEPTION WARNING:
• No adverse effects on male or female fertility observed in animal studies at therapeutic doses
Expert advice:
1. START LOW AND ESCALATE SLOWLY — PATIENCE IS KEY:
• Mounjaro 12.5mg is never used as a starting dose. The mandatory escalation begins at 2.5mg once weekly for 4 weeks before advancing. This gradual approach significantly reduces the severity of nausea, vomiting, and gastrointestinal discomfort. Do not skip escalation steps to reach 12.5mg faster — this increases dropout rates due to side effects.
2. COLD-CHAIN STORAGE IS ESSENTIAL — CHECK YOUR PEN ON RECEIPT:
• Tirzepatide must be stored between 2°C and 8°C at all times. At Shabbir Medical Hall, we ship all Mounjaro pens with ice packs in temperature-controlled packaging. On receipt, inspect the pen: if the solution appears cloudy, discoloured, or contains particles, do not use it. Once removed from the refrigerator, the pen can be stored at room temperature (up to 30°C) for a maximum of 21 days.
3. ROTATE INJECTION SITES EVERY WEEK:
• Use the abdomen (avoid the 2-inch area around the navel), upper thigh, or upper arm as injection sites. Rotate the site with each weekly injection to prevent lipodystrophy (fat tissue changes at injection site), which can alter drug absorption. Never inject into skin that is tender, bruised, red, or hard.
4. NAUSEA IS NORMAL — BUT KNOW WHEN TO WORRY:
• Mild to moderate nausea, especially in the first 4–8 weeks or after each dose escalation, is expected and usually self-limiting. Reduce high-fat, spicy, or greasy foods; eat smaller, more frequent meals; avoid eating immediately before the injection. However, severe persistent vomiting, inability to tolerate fluids, or abdominal pain radiating to the back must be reported immediately — these could signal pancreatitis.
5. KNOW THE THYROID WARNING SIGNS:
• Mounjaro carries a boxed warning for thyroid C-cell tumours (observed in animal studies). While the risk in humans remains unproven, patients should be counselled to monitor for a neck lump, difficulty swallowing, persistent hoarseness, or unexplained neck pain, and report these immediately. Mounjaro is strictly contraindicated if you or a blood relative has been diagnosed with Medullary Thyroid Carcinoma or MEN 2.
MONITORING SCHEDULE:
• Baseline: HbA1c, fasting blood glucose, body weight, BMI, blood pressure, renal function, lipid panel, thyroid history
• 4 weeks after each dose escalation: Tolerance assessment, blood glucose, body weight
• 3 months after reaching maintenance dose: HbA1c, fasting glucose, body weight, blood pressure
• Every 6 months: HbA1c, body weight, renal function, lipid panel
• Annual: Comprehensive metabolic panel, gallbladder assessment if symptomatic, retinal review in T2DM
COMPLIANCE TIPS:
• Set a fixed weekly day for injection (e.g., every Monday) — mark on calendar or set phone reminder
• Keep pen in refrigerator door — visible reminder; never in freezer
• Carry a small insulated pouch with ice pack for travel — a 21-day room temperature window gives flexibility for holidays
• Keep a weekly weight and blood glucose diary if prescribed monitoring — bring to every clinic visit
• Never share your KwikPen with another person — risk of blood-borne infection transmission
SAFETY TIPS:
• Carry a medical alert card noting you are on Tirzepatide injection — especially relevant for emergency presentations
• Inform all treating doctors, dentists, and emergency physicians that you are on Mounjaro
• Avoid alcohol excess during treatment — increases risk of pancreatitis and hypoglycaemia
• If switching from another GLP-1 agonist (Semaglutide, Liraglutide), inform your doctor — do not combine; allow appropriate wash-out if switching
Side Effects:
• Nausea: Most common — particularly during dose escalation; usually mild to moderate, subsides over time
• Vomiting: Often accompanies nausea during escalation phase; report if persistent or severe
• Diarrhoea: Loose stools, increased frequency — ensure adequate hydration
• Decreased Appetite: Expected and beneficial in weight management; ensure adequate nutritional intake
• Indigestion / Abdominal Pain: Bloating, reflux, or epigastric discomfort — usually transient
• Constipation: Less common; ensure adequate fluid and fibre intake
• Injection Site Reactions: Redness, bruising, or mild discomfort at injection site — rotate sites weekly
SERIOUS SIDE EFFECTS — SEEK IMMEDIATE MEDICAL HELP:
ACUTE PANCREATITIS — RARE BUT SERIOUS: STOP MEDICINE AND SEEK EMERGENCY CARE if you experience:
• Severe, persistent abdominal pain radiating to the back
• Nausea and vomiting with severe abdominal pain
• Do NOT restart without physician clearance; history of pancreatitis is a relative contraindication
THYROID C-CELL TUMOURS (MEDULLARY THYROID CARCINOMA — MTC) — THEORETICAL RISK:
• Observed in animal studies; human relevance unknown but CONTRAINDICATED if personal/family history of MTC or MEN 2
• Monitor for: neck lump, difficulty swallowing, hoarseness, persistent neck pain — report immediately
ACUTE GALLBLADDER DISEASE (CHOLELITHIASIS / CHOLECYSTITIS):
• Rapid weight loss increases gallstone risk — report severe right upper abdominal pain, fever, jaundice
HYPOGLYCAEMIA (when used with insulin or sulphonylureas):
• Risk is low as monotherapy; significant risk when combined with insulin/sulphonylurea — reduce insulin/SU dose on initiation
How to use:
TYPE 2 DIABETES / WEIGHT MANAGEMENT:
• Starting dose: 2.5mg subcutaneous injection once weekly for 4 weeks (initiation dose — not for glycaemic effect)
• Dose escalation: Increase by 2.5mg increments every 4 weeks based on tolerability: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg (→ 15mg if needed and tolerated)
• Maintenance dose: 12.5mg once weekly (for patients who tolerated 10mg but need additional control)
• Maximum dose: 15mg once weekly
ROUTE OF ADMINISTRATION:
• Inject subcutaneously into the abdomen, thigh, or upper arm
• Rotate injection sites weekly to prevent lipohypertrophy
• Do not inject into muscle or vein
TIMING:
• Can be administered at any time of day, with or without food
MISSED DOSE:
• If a dose is missed: take within 4 days (96 hours); if >4 days have passed, skip and take next dose on scheduled day
STORAGE:
• Store in refrigerator between 2°C and 8°C in original carton; protect from light
• Do NOT freeze — discard if frozen
• Once removed from refrigerator: can be kept at room temperature (up to 30°C) for a maximum of 21 days
• Keep out of reach of children; do not use after expiry date
How it works:
Mounjaro 12.5mg contains Tirzepatide — the world's first and only dual GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptor agonist.
• GLP-1 receptor activation: Stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses inappropriate glucagon secretion, delays gastric emptying, and reduces appetite via central nervous system satiety signals
• GIP receptor activation: Enhances insulin secretion from beta cells (additive to GLP-1 effect), promotes adipocyte lipid metabolism, and contributes to the superior weight loss effect compared to GLP-1 mono-agonists
• Dual activation results in: Greater HbA1c reduction than either GIP or GLP-1 agonism alone, substantially greater body weight reduction (up to ~20% in some subgroups), improved insulin sensitivity
• Insulin-independent appetite suppression and slowed gastric emptying reduce calorie intake significantly
KEY ADVANTAGE:
• HbA1c reduction: approximately 1.87–2.58% from baseline at the 12.5mg dose (SURPASS-1 to SURPASS-5 programme)
Faq for medicine:
Mounjaro 12.5mg KwikPen delivers Tirzepatide 12.5mg weekly, providing substantial HbA1c reductions of approximately 2.0–2.3% from baseline in type 2 diabetes patients. It also produces significant weight loss of 10–12% of body weight. Mounjaro 12.5mg activates both GIP and GLP-1 receptors, offering superior glycaemic control and metabolic benefits compared to most currently available diabetes medications in its drug class.
2.How does Mounjaro 12.5mg KwikPen support weight management in diabetes?
Mounjaro 12.5mg KwikPen (Tirzepatide) significantly reduces body weight in type 2 diabetes patients through appetite suppression and slowed gastric emptying. In the SURPASS clinical trial program, patients on 12.5mg achieved mean weight reductions of approximately 10–12 kg. This degree of weight loss rivals dedicated anti-obesity medications. Mounjaro 12.5mg benefits overweight and obese type 2 diabetes patients beyond glycaemic management alone.
3.What is the correct injection technique for Mounjaro 12.5mg KwikPen?
Mounjaro 12.5mg KwikPen is injected subcutaneously once weekly using the prefilled auto-injector. Suitable injection sites include the abdomen, thigh, or upper arm. Sites should be rotated weekly to prevent lipohypertrophy. Press the KwikPen firmly against skin until the injection is complete. Do not inject into skin that is tender, damaged, or bruised. Store unused pens refrigerated at 2–8°C, protected from direct sunlight.
4.Are there any drug interactions with Mounjaro 12.5mg KwikPen to be aware of?
Mounjaro 12.5mg KwikPen (Tirzepatide) slows gastric emptying, which may delay the absorption of orally administered medications, including hormonal contraceptives and thyroid drugs. Oral contraceptives should ideally be switched to non-oral forms or used with barrier protection during Mounjaro initiation. Concurrent use with insulin or sulfonylureas increases hypoglycaemia risk. Physicians should review all medications before prescribing Mounjaro 12.5mg.
5.Who should not use Mounjaro 12.5mg KwikPen due to contraindications?
Mounjaro 12.5mg KwikPen is contraindicated in patients with type 1 diabetes, personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2. It is not approved for use during pregnancy or breastfeeding. Patients with severe gastrointestinal disease, prior pancreatitis, or hypersensitivity to Tirzepatide should not use Mounjaro. Medical history must be thoroughly reviewed before prescribing.
6.Can Mounjaro 12.5mg KwikPen be used in patients with obesity without diabetes?
Mounjaro 12.5mg KwikPen (Tirzepatide) is under evaluation for obesity management without diabetes. Under the brand name Zepbound, Tirzepatide is approved for chronic weight management in adults with obesity or overweight with weight-related comorbidities. Mounjaro 12.5mg may be prescribed off-label for obesity in some regions, but its primary approved indication remains type 2 diabetes glycaemic management alongside diet and exercise.
Medicine interaction:
• Insulin / Sulphonylureas (Glipizide, Glimepiride): Risk of hypoglycaemia — reduce insulin or sulphonylurea dose by 20–50% when initiating Tirzepatide; monitor blood glucose closely
• Oral Contraceptives: Tirzepatide delays gastric emptying — may reduce absorption of oral contraceptives; use additional contraception for 4 weeks after each dose escalation
• Oral Medications with Narrow Therapeutic Index (Warfarin, Digoxin, cyclosporine): Delayed gastric emptying may alter absorption — monitor drug levels and therapeutic effect closely
• Metformin / SGLT2 Inhibitors (Empagliflozin, Dapagliflozin): Safe and effective combinations — no clinically significant pharmacokinetic interaction; complementary mechanisms
• GLP-1 Agonists (Semaglutide, Liraglutide): DO NOT combine — redundant mechanism; risk of additive GI side effects without additional benefit
VACCINE INTERACTIONS:
• No specific vaccine interactions documented for Tirzepatide
SUPPLEMENT INTERACTIONS:
• Blood glucose-lowering supplements (Berberine, Bitter Melon, Chromium): Inform physician — risk of hypoglycaemia especially with insulin/sulphonylurea co-therapy
• Inform all treating physicians that you are on Tirzepatide before any procedure, surgery, or hospitalisation
DIAGNOSTIC CONSIDERATIONS:
• Calcitonin levels: Tirzepatide may slightly increase calcitonin — inform endocrinologist if thyroid workup is planned
• Pancreatic enzymes: Mild asymptomatic elevations of lipase/amylase may occur — clinical significance unclear without symptoms
